Drug Trial Radar · NCT07444814
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
226
Planned (sponsor's estimate)
Start
Dec 19, 2025
Primary completion
Sep 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Whitehawk Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.
Conditions
- Endometrial Cancer
- Ovarian Cancer
- Ovarian Cancer Metastatic
- Ovarian Cancer Metastatic Recurrent
- Non-squamous EGFR Wt NSCLC
- Platinum Resistant Ovarian Cancer
- PROC
Interventions
HWK-007Drug
HWK-007 is a PTK7- targeted ADC being developed for the treatment of solid tumors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine Maximum Tolerated Dose (MTD)Time frame: From Cycle 1, Day 1 until Cycle 1, Day 21 (21-day cycles)
- Determine Maximum Administered Dose (MAD)Time frame: From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles)
- Determine the Recommended Dose for Expansion (RDE)Time frame: From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles) until MTD or MAD is identified.
- Determination of Recommended Phase 2 Dose (RP2D) (Phase 1b)Time frame: From Cycle 1 Day 1 to End of Primary Completion
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama · Recruiting
University of Arizona Cancer Center
Tucson, Arizona · Recruiting
University of Arkansas
Little Rock, Arkansas · Recruiting
UCLA - Hematology/Oncology Clinical Research Unit
Los Angeles, California · Recruiting
Stanford Cancer Institute, Stanford University
Palo Alto, California · Recruiting
St. Francis Medical Center (OSF Healthcare)
Peoria, Illinois · Recruiting
University of Maryland
Baltimore, Maryland · Recruiting
START - Midwest
Grand Rapids, Michigan · Recruiting
Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, New Jersey · Recruiting
Roswell Park Comprehensive Care Center
Buffalo, New York · Recruiting
University Hospital - Cleveland Medical Center
Cleveland, Ohio · Recruiting
NEXT Oncology - Austin
Austin, Texas · Recruiting
NEXT - Oncology - Houston
Houston, Texas · Recruiting
START - San Antonio
San Antonio, Texas · Recruiting
NEXT Oncology - Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.